Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum

Harvard Bioscience (Nasdaq: HBIO) announced that CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17, 2026.

Rhea-AI Summary

Harvard Bioscience (Nasdaq: HBIO) announced that CEO John Duke and Interim CFO Mark Frost will participate in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17, 2026.

A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET, with an audio-only webcast option available via the events and presentations section.

Argus Mar 3 session

-4.31% close to close Open Argus

Details

News Market Reaction – HBIO

In the Mar 3 session, HBIO declined 4.31%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Harvard Bioscience’s participation in a virtual healthcare forum, inclu...

Analysis

This announcement highlights Harvard Bioscience’s participation in a virtual healthcare forum, including a fireside chat at 2:15pm ET on March 17. It reinforces ongoing investor outreach following recent refinancing, restructuring, and preliminary earnings updates. Investors may focus on how management messages around cost savings, balance sheet changes, and strategic priorities evolve at such events, and track upcoming milestones like the scheduled earnings call and any further regulatory filings or capital structure developments.

Key Figures

Forum date: March 17 Fireside chat time: 2:15pm ET

Forum date

March 17

KeyBanc Capital Markets Virtual Healthcare Forum

Fireside chat time

2:15pm ET

Scheduled webcast from investor relations website

Historical Context

5 past events · Latest: Feb 26

5 events

1. Feb 26

   Earnings call scheduled

   24h Move

   -0.5%

   Set date for Q4 2025 results and earnings call webcast.

2. Feb 10

   Prelim Q4 results

   24h Move

   +13.4%

   Preliminary Q4 beat on revenue and margins, EBITDA growth and 2026 focus.

3. Jan 29

   Manufacturing consolidation

   24h Move

   -6.7%

   Announced plant closure and global production shift for long-term savings.

4. Dec 17

   Debt refinancing

   24h Move

   +12.4%

   Secured new $40.0M credit facility to refinance debt and extend maturities.

5. Nov 06

   Q3 2025 earnings

   24h Move

   -7.3%

   Reported net loss and goodwill impairment despite guidance and backlog strength.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief Financial Officer, will be participating in KeyBanc Capital Markets’ Virtual Healthcare Forum on Tuesday, March 17^th. A fireside chat will be broadcast from the company’s investor relations website at 2:15pm ET that day.

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.

About Harvard Bioscience 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Company Contact:
Mark Frost
Interim Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Harvard Bioscience (HBIO) present at KeyBanc’s Virtual Healthcare Forum?

Harvard Bioscience will present on Tuesday, March 17, 2026 at 2:15pm ET. According to the company, the session is a fireside chat featuring CEO John Duke and Interim CFO Mark Frost broadcast from the investor relations website.

Who from Harvard Bioscience (HBIO) will speak at the March 17, 2026 forum?

CEO John Duke and Interim CFO Mark Frost will participate in the forum. According to the company, they will join a fireside chat hosted by KeyBanc Capital Markets and be available via the investor relations webcast.

How can investors access Harvard Bioscience’s (HBIO) webcast on March 17, 2026?

Investors can watch the fireside chat on the company’s investor relations website at the scheduled time. According to the company, an audio-only webcast option is available under Events and Presentations on the investor site.

Will the Harvard Bioscience (HBIO) presentation at the forum include an audio-only option?

Yes. An audio-only webcast option is available for the March 17, 2026 session. According to the company, participants should visit Events and Presentations on the investor relations website to join the audio-only feed.

What topics will Harvard Bioscience (HBIO) cover during the KeyBanc Virtual Healthcare Forum?

The announcement lists a fireside chat but does not detail topics. According to the company, CEO John Duke and Interim CFO Mark Frost will participate; investors can view the webcast for the full discussion and context.